Spinal muscular atrophy type 2 is less common and less severe than type 1. Symptoms typically begin within 18 months of birth. With treatment and supportive devices, people with the disease often live ...
The child living with spinal muscular atrophy (SMA) type 2 had less fatigue and improved functional scores as time went on. The use of a gait exoskeleton appears to lead to benefits in terms of ...
Using disease-modifying therapies may help children with SMA types 1 and 2 maintain better nutrition and prevent stunted ...
The new report is based on real-world data from a patient registry and shows some patients even regain motor function under treatment with nusinersen for spinal muscular atrophy (SMA). A new ...
"Decreasing AMMO [active maximal mouth opening] over time is seen most often in patients with SMA type 2 with an estimated reduction of almost 1 mm per year...At this point, we propose that ...
PHILADELPHIA--(BUSINESS WIRE)--Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 ...
Patients treated with OAV101 IT showed an increase from baseline in HFMSE total score compared with sham control. Topline data were announced from a phase 3 trial evaluating intrathecal onasemnogene ...
– Phase 3 trial is a randomized, double-blind, placebo-controlled trial of apitegromab as add-on to background SMN therapy in non-ambulatory Type 2/3 SMA – Trial design is informed by the positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results